For much of the past year, the UK’s medicines pricing debate has cast a long shadow over the life sciences sector. The deadlock over NHS rebates – and the uncertainty surrounding the successor to VPAG ...
As global capital trickles back toward China, policymakers are signalling they want growth without the froth, using tougher enforcement and cooling measures to slow the market's pace in order to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results